Bronchitis News and Research

RSS

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).

Anthem Blue Cross and Blue Shield launches initiative to educate consumers on how to best access ER alternatives

At a time when health care costs continue to rise and hospitals are advertising emergency room availability, it is becoming more important to educate consumers on how to best access ER alternatives and receive the same care with less out-of-pocket cost. If a primary care physician isn't available, retail health clinics, walk-in doctor offices and urgent care centers can take less time and cost about the same as a regular doctor visit.

22 Jul 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

Rotech Healthcare accepts 17 CMS contracts in Round 1 Rebid of Medicare Competitive Bidding Program

Rotech Healthcare Inc. today announced that it has accepted 17 contracts awarded by the Centers for Medicare & Medicaid Services in the Round 1 Rebid of the national Medicare Competitive Bidding Program. The Round 1 Rebid included nine metropolitan statistical areas. Only contracted suppliers can service Medicare patients for the competitively-bid product categories in these locations, with a few exceptions. The new contracts awarded in Round 1 have a three-year term and are scheduled to take effect on January 1, 2011.

13 Jul 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

DRIVE4COPD initiative aims to raise awareness of COPD

In just four months since its launch, DRIVE4COPD has already encouraged more than 100,000 people to be screened to see if they may be at risk for chronic obstructive pulmonary disease. The country's newest health initiative that aims to raise awareness of COPD in the hopes that people will talk to their doctor and get diagnosed instead of suffering in silence. Currently, half of the estimated 24 million Americans who may have COPD remain undiagnosed and untreated, and most are not diagnosed until they have lost half their lung function.

11 Jun 2010

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it has entered into an agreement with Boston-based Stethographics, Inc. providing an exclusive license to patented, FDA-cleared Stethographics lung sounds analysis technology that automatically identifies clinically significant respiratory sounds.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Chronic insomnia increases mortality risk

Individuals with chronic insomnia have an elevated risk of death, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Centocor Ortho Biotech acquires RespiVert

Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).

1 Jun 2010

Beta-blocker medications provide new hope for patients with COPD: Study

Patients with chronic obstructive pulmonary disease may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

25 May 2010

Washington State Department of Health shows smoking inside homes drops by 61% since 2000

New research released today by the Washington State Department of Health shows the number of people smoking inside homes in our state has declined by 61 percent since 2000. The drop is more than double the overall decline in adult smoking during the same period.

21 May 2010

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

In this economy, allergy sufferers are looking for relief from more than sneezing, runny noses, and itchy eyes. And, according to a recent study, they can find relief for both their symptoms and their wallets, saving anywhere from $50 to $400 in out-of-pocket costs per visit if they skip the emergency room and head to urgent care and retail health clinics when they are unable to see their primary physician.

20 May 2010

FDA issues complete response letter for roflumilast NDA

Forest Laboratories, Inc. and Nycomed today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast. Roflumilast was reviewed as a potential treatment to reduce COPD exacerbations associated with chronic bronchitis in patients at risk for exacerbations.

18 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.

10 May 2010

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

10 May 2010

Natural plant extract could help treat COPD and inflammatory disorders

A widely and safely used plant extract acts as a novel anti-inflammatory agent that may one day be used for the treatment of chronic obstructive pulmonary disease, or COPD, as well as other inflammatory conditions.

4 May 2010

WHO issues guidance on ash cloud from Iceland volcanic explosion

The ash cloud from the volcanic explosion in Iceland contains fine particles, similar to those emitted from other sources of particulate matter (PM); but as long as ash remains in the upper atmosphere, there will not likely be an increased risk of health effects, according to WHO.

17 Apr 2010

Bronchitis News and Research

Further Reading

Anthem Blue Cross and Blue Shield launches initiative to educate consumers on how to best access ER alternatives

Forest Laboratories reports first-quarter diluted EPS of $0.39

Rotech Healthcare accepts 17 CMS contracts in Round 1 Rebid of Medicare Competitive Bidding Program

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

DRIVE4COPD initiative aims to raise awareness of COPD

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Chronic insomnia increases mortality risk

Centocor Ortho Biotech acquires RespiVert

Beta-blocker medications provide new hope for patients with COPD: Study

Washington State Department of Health shows smoking inside homes drops by 61% since 2000

Allergy sufferers can save out-of-pocket costs by visiting urgent care and retail health clinics instead of ER

FDA issues complete response letter for roflumilast NDA

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Urgent care and retail health clinics can reduce treatment costs for allergy sufferers

Natural plant extract could help treat COPD and inflammatory disorders

WHO issues guidance on ash cloud from Iceland volcanic explosion

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News